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Summary
 
The signals that direct differentiation of T cells to the CD4 or CD8 lineages in the thymus re-
main poorly understood. Although it has been relatively easy to direct differentiation of CD4
single positive (CD4
 
1
 
) cells using combinations of antibodies
 
 
 
and pharmacological agents that
mimic receptor engagements, equivalent stimuli do not induce efficient maturation of CD8
 
1
 
cells. Here we report that, irrespective of the MHC-restriction specificity of the TCR, differ-
entiation of mature CD8
 
1
 
 thymocytes can be induced by ligation of CD3 polypeptides on im-
mature thymocytes with a F(ab
 
9
 
)
 
2
 
 reagent (CD3fos-F(ab
 
9
 
)
 
2
 
). The tyrosine phosphorylation pat-
terns stimulated by CD3fos-F(ab
 
9
 
)
 
2
 
 have been shown to resemble those delivered to mature T
cells by antagonist peptides, which are known to direct positive selection of CD8
 
1
 
 cells, and
we can show that this reagent exhibits potent antagonistic-like activity for primary T cell re-
sponses. Our results suggest a distinction in the signals that specify lineage commitment in the
thymus. We present a model of thymocyte differentiation that proposes that the relative bal-
ance of signals delivered by TCR engagement and by p56
 
lck
 
 activation is responsible for direct-
ing commitment to the CD8 or CD4 lineages.
 
T
 
he question of whether distinct biochemical signals
specify commitment to the CD4 or CD8 lineage in
the thymus is currently unresolved. Receptor engagements
that induce differentiation of CD4
 
1
 
 T cells appear to be
relatively promiscuous, in that they can be mimicked by
antibodies interacting with a variety of molecules on the
immature thymocyte surface. Examples include hybrid an-
tibodies that target thymocytes via their TCRs to thymic
cortical epithelium (1), extensive engagement of TCR-
 
b
 
chains with antibody (2), and coligation of the TCR–CD3
complex on immature thymocytes with various surface
molecules such as CD2 (1, 3), CD4, or CD8 (4), and even
CD5, CD24, CD28, CD49d, and CD81 (3). Moreover,
most of these receptor engagements are capable of inducing
proliferation of mature T cells and thus resemble agonistic
stimuli. 
In contrast, positive selection of murine CD8
 
1
 
 T cells
has been reproduced successfully in thymic organ cultures
(TOCs)
 
1
 
 only by presentation of more specific stimuli, such
as the positively selecting MHC class I molecule together
with altered peptide ligands with antagonist (5) or partial
agonist (6) activity. It should be noted that equivalent stim-
uli do not induce, but rather inhibit, differentiation of
CD4
 
1
 
 cells (7). The selection of CD8
 
1
 
 T cells expressing
MHC class I–restricted transgenic TCRs by low concen-
trations of the nominal peptide or a weak agonist has also
been reported (6, 8, 9). However, T cells that had been se-
lected on such ligands are aberrant in that they seem to
have adjusted their stimulation threshold and are no longer
responsive to the selecting peptide (9, 10). Thus, CD8
 
1
 
cells are positively selected by stimuli that do not induce
significant proliferation in mature T cells. Finally, evidence
that different signaling pathways may be engaged during
differentiation of the CD4 and CD8 lineages in the thymus
has been suggested by studies that have shown that PMA
stimulation of immature thymocytes in the presence of the
Ca
 
2
 
1
 
 ionophore ionomycin promotes full maturation of
CD4 but not CD8 cells (11, 12).
To dissect the differential signaling requirements for pos-
itive selection of CD4 and CD8 lineages, our aim was to
mimic the partial, antagonist-like signals perceived by a
TCR upon engagement of some altered peptide ligand/
MHC complexes. CD3–TCR-specific F(ab
 
9
 
)
 
2
 
 reagents
 
1
 
Abbreviations used in this paper:
 
 BsAb, bispecific F(ab
 
9
 
)
 
2
 
; DC, dendritic
cell; DN, double negative; DP, double positive; HSA, heat-stable anti-
gen; NP, nucleoprotein; TOC, thymic organ culture.
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CD3
 
e
 
 Ligation Induces CD8
 
1
 
 Thymocyte Maturation
 
have been used as nonmitogenic alternatives to the intact
parent antibodies for immunomodulation of autoimmune
responses and graft rejection (13–15). These reagents, by
virtue of their absent Fc portions, are capable of engaging
the TCR–CD3 complex while failing to fully activate ma-
ture T cells to proliferate and secrete significant quantities
of cytokines (13–15). Recently, the early signaling events
triggered by such F(ab
 
9
 
)
 
2
 
 reagents were examined directly
and shown to bear a striking resemblance to those induced
by altered peptide ligands (16, 17). Furthermore, the inabil-
ity of these reagents to induce full stimulation was shown
to correlate with a lack of coreceptor-associated p56
 
lck
 
 re-
cruitment to the TCR–CD3 complex (16).
In the thymus it has been suggested that development of
the CD4 lineage is favored by increasing the level of p56
 
lck
 
recruitment to the TCR complex (18). We have shown
previously that coligation of CD3
 
e
 
 with either CD4 or
CD8 with bispecific F(ab
 
9
 
)
 
2
 
s (BsAb) induces maturation of
CD4
 
1
 
 cells in TOCs (4). The CD3/CD4 BsAb was more
efficient than the CD3/CD8 BsAb at inducing CD4
 
1
 
 
 
dif-
ferentiation, consistent with the observation that CD4 asso-
ciates more efficiently with lck (19), and can thus bring lck
into proximity with the TCR more effectively, and that
such recruitment favors CD4
 
1
 
 
 
differentiation (18). A ge-
netically engineered CD3
 
e
 
-specific F(ab
 
9
 
)
 
2
 
 fragment de-
rived from 2C11 V-regions (20) induced no CD4
 
1
 
 matu-
ration in these experiments (4). Here we show that this
CD3fos-F(ab
 
9
 
)
 
2
 
 reagent is able to mimic the signals re-
quired for CD8
 
1
 
 thymocyte differentiation, enabling us to
investigate directly the role of partial signals in the differen-
tiation of single positive thymocytes.
 
Materials and Methods
 
Mice.
 
The 
 
b
 
2 microglobulin–deficient (
 
b
 
2m
 
2
 
) and I-A
 
b
 
–
deficient (MHC class II
 
2
 
) mice have been previously described
(references 21 and 22, respectively) and were intercrossed to obtain
 
b
 
2m
 
2
 
3
 
class II
 
2
 
 (MHC
 
2
 
) mice. TCR transgenic mice back-
crossed onto a RAG-1–deficient (RAG-1
 
2
 
) background (23)
were as follows: MHC class I–restricted F5 TCR (24), specific for
influenza nucleoprotein (NP), restricted by H-2D
 
b
 
, and MHC
class II–restricted A18 TCR (25), specific for C5 in the context
of I-E
 
k
 
. Male studs, homozygous for the TCR transgenes on the
appropriate backgrounds (RAG-1
 
2
 
/
 
b
 
2m
 
2
 
 for F5 and RAG-1
 
2
 
for A18), were bred with RAG-1
 
2
 
/
 
b
 
2m
 
2
 
 or RAG-1
 
2
 
 females,
respectively, yielding neonates from which thymus lobes were
obtained.
 
Antibodies.
 
Bi- and monospecific F(ab
 
9
 
)
 
2
 
 antibodies dimer-
ized through Fos or Jun leucine zippers were prepared as previ-
ously described (20). V-regions with specificity for CD3
 
e
 
, CD4,
or CD8
 
a
 
 were derived from 145.2C11, GK1.5, and YTS169.
Monoclonal antibodies were purified and conjugated with FITC
or biotin in our own laboratory, unless stated otherwise. The
TCR-
 
z
 
–specific mAb, MCA146, was a gift from S. Ley (NIMR,
London, UK), rabbit antiserum and mAb (3.3.1) to ZAP-70 was
from J. Tite (Glaxo Wellcome, Stevenage, UK), and rabbit anti-
serum to p56
 
lck
 
 was kindly provided by A. Magee (NIMR, Lon-
don, UK). 
 
Thymus Organ Culture.
 
Neonatal (day of birth) thymus lobes
were cultured for 3–4 d as previously described (4) with the indi-
cated antibodies or with medium only. Lobes were transferred to
fresh filters in culture medium without antibody and cultured for
a further 2–4 d to allow reexpression of downmodulated mole-
cules. Single cell suspensions prepared from lobes after culture
were stained with FITC-CD8
 
a
 
– (YTS169.4 or KT15; Fig. 5) or
FITC-CD8
 
b
 
– (KT112-1), PE-CD4– (Boehringer Mannheim,
Lewes, UK), and biotin–heat-stable antigen (HSA)– (YBM5.10),
biotin-V
 
b
 
11– (KT11.5, for F5 TCR), biotin-V
 
b
 
8.3– (F23.1, for
A18 TCR) or biotin-pan-TCR-
 
b
 
– (H57.597; see Fig. 2) specific
antibodies, followed by Streptavidin-RED670 (GIBCO BRL,
Paisley, UK) and 20,000 live events (gated on forward and side
scatter profiles) were analyzed on a FACScan
 
Ò
 
 (Becton Dickin-
son, Oxford, UK).
 
CTL Assay.
 
Dendritic cells (DCs) were expanded by culture
of B10 (H-2
 
b
 
) bone marrow in medium supplemented with GM-
CSF for 7 d (26). Thymocytes from lobes cultured with either 10
 
m
 
g/ml CD3fos-F(ab
 
9
 
)
 
2
 
 or medium were stimulated at 7 
 
3 
 
10
 
4
 
/
well with 2.5 
 
3 
 
10
 
4
 
 H-2
 
b
 
 DCs/well and 1 
 
m
 
M NP68 peptide for
4 d at 37
 
8
 
C in medium plus 10% rIL-2 supernatant. On day 4,
cells were harvested, resuspended to equivalent volumes, and ti-
tered with 10
 
3
 
 
 
51
 
Cr-labeled NP68-loaded EL-4 targets/well for 4 h,
after which 100 
 
m
 
l supernatant was removed for 
 
g
 
 counting. Per-
centage of specific lysis was calculated as [(cpm experimental re-
lease 
 
2
 
 cpm
 
 
 
spontaneous release)/(cpm maximum release 
 
2 
 
cpm
spontaneous release)] 
 
3 
 
100.
 
Proliferation and Antagonism Assays.
 
B10 thymocytes (10
 
6
 
/well)
were incubated for 72 h with 2C11, CD3/CD8, CD3/CD4, and
CD3fos-F(ab
 
9
 
)
 
2
 
 in medium (triplicate cultures). In antagonism as-
says, splenocytes (2 
 
3 
 
10
 
5
 
/well) from A18/RAG-1
 
2
 
 
 
or F5/
RAG-1
 
2
 
 
 
mice were cultured in the presence of C5 or NP68 pep-
tides, respectively, at indicated concentrations (see legend to Fig. 6).
CD3fos-F(ab9)2, a nonbinding control reagent, CD4/CD4, and an
anti–Thy-1 antibody (YTS 154.7) were added at the concentra-
tions indicated at the start of culture. Cultures were pulsed with
1 mCi [3H]thymidine per well for the last 18 h of culture, har-
vested, and counted in a beta counter with scintillation. The up-
regulation of CD69 during antagonism assays was measured over
time by staining aliquots of the cultures with PE-CD4–, FITC-
Vb8.3– (A18), or PE-CD8a– (Sigma Chemical Co., Poole, UK)
(F5) and biotin-CD69– (PharMingen, San Diego, CA) specific
antibodies and CD69 expression on CD41Vb8.31 (A18) or
CD81 (F5) cells analyzed by flow cytometry.
Phosphotyrosine Analyses. Thymocytes from F5/RAG-12/b2m2
mice (95% double positive [DP], 5% double negative [DN] cells)
were kept at 48C on ice and stimulated for 5–20 min at 378C with
saturating amounts of antibody (100 mg/ml per 1–2 3 108 thy-
mocytes). Cells were pelleted at 13,000 rpm for a few seconds
and lysed for 1 h at 48C in 1% Brij or Triton X-100 (for ZAP-70
immunoprecipitations) in 150 mM NaCl, 50 mM Tris (pH 7.5),
5 mM EDTA, 10 mM NaF, 10 mM disodiumpyrophosphate,
200 mM PMSF, 5 mM leupeptin, 1.5 mM pepstatin A, and 1 mM
Na3VO4. Postnuclear supernatants were precipitated overnight at
48C with 20 ml protein A–Sepharose (PAS), covalently coupled
to anti–TCR-z mAb (MCA146); rabbit anti–ZAP-70 SH2 serum
and PAS; or rabbit anti-lck peptide serum and PAS. Precipitates
were washed 33 in lysis buffer, dissolved in reducing sample buffer,
and resolved on a 7–15% gradient SDS-PAGE gel. Proteins were
transferred electrophoretically onto a nylon membrane, blocked
in 5% nonfat milk powder in PBS with 0.1% Tween 20, and
blotted with antiphosphotyrosine (4G10, Upstate Biotechnology,
Inc., Lake Placid, NY) or anti–ZAP-70 mAbs. Anti–mouse Ig-
horseradish peroxidase conjugate antibodies (Southern Biotech-1251 Basson et al.
nology Associates, Inc., Birmingham, AL) developed with ECL
(Boehringer Mannheim, Lewes, UK) were used for detection. 
Results
CD3fos-F(ab9)2 Induces Differentiation of CD81 Thymocytes.
To investigate whether we could induce differentiation of
CD8 thymocytes, we used a variety of mouse strains in
which normal CD8 differentiation was impaired. Initially
thymuses were obtained from mice transgenic for the MHC
class I–restricted TCR, F5 (24), specific for influenza NP
restricted by H-2Db and back-crossed to the RAG-12/
b2m2 background. The lack of MHC class I in these mice
impairs maturation of significant numbers of CD81 thy-
mocytes, and those that fall within the CD81 gate contain
only a small fraction of mature HSAlo cells (Fig. 1 A, me-
dium control). However, when newborn thymus lobes
from F5/RAG-12/b2m2 mice were cultured in the pres-
ence of CD3fos-F(ab9)2, but not control CD8jun-(Fab9)2,
reagents, differentiation of significant numbers of CD81
cells occurred that had downregulated expression of HSA
(Fig. 1 A). Furthermore, these cells also stained brightly for
the CD8b chain (data not shown), indicating that they be-
long to the TCR-a/b and not the g/d lineage, since the
majority of CD81 T cells that belong to the g/d lineage
preferentially express CD8a/a homodimers on their sur-
face (27).
The absolute number of TCRhi CD81 cells generated
from F5/RAG-12/b2m2-derived thymus lobes was de-
pendent on CD3fos-F(ab9)2 concentration, with 5–10 mg/ml
inducing a 5–10-fold increase above background (Fig. 2).
Therefore, the efficiency of positive selection induced by
CD3fos-F(ab9)2 is directly comparable to that induced by
altered peptide ligands for the OVA–tcr-1 transgenic mice
on a b2m2 background (3–9-fold increase) (5), a naturally
occurring positively selecting peptide of the OT-1 TCR
on a TAP-12 background (7-fold increase) (28) and more
efficient than was reported for P14 TCR transgenic mice
Figure 1. CD3fos-F(ab9)2 (CD3/CD3) induces the differentiation of mature CD81 cells and antagonizes the normal differentiation of CD41 T cells in
neonatal thymus lobes. Newborn thymus lobes from (A) MHC class I–restricted F5/RAG-12/b2m2 transgenic (24); (B) class II–restricted A18/RAG-12
transgenic (25); (C) b2m2; and (D) MHC2 (class II2b2m2) mice were cultured with 5 mg/ml (A and B), 50 mg/ml (C), or 20 mg/ml (D) CD3fos-F(ab9)2
(CD3/CD3) or CD8jun-F(ab9)2 (CD8/CD8). Dot-plots show CD8 and CD4 expression of all thymocytes recovered from a single lobe. The percentage
of total cells for individual subpopulations are indicated. HSA levels of CD41 (thick line), DP (light fill) and CD81 (dark fill) subpopulations are presented
in histograms below each dot-plot. The data are representative of 13 (A), 8 (B), 6 (C), and 4(D) independent experiments.1252 CD3e Ligation Induces CD81 Thymocyte Maturation
on a TAP-12 background (2–4-fold increase) (6) or for a
mixture of thymic self-peptides in fetal TOCs from TAP-12
mice (3-fold increase) (29). Furthermore, the final percent-
ages (20–30%) of CD81 cells and corresponding numbers
of mature, TCRhi CD81 cells (z7 3 104) recovered from
F5/RAG-12/b2m2 thymuses after treatment with CD3
fos-F(ab9)2, are comparable to the level of positive selection
observed under optimal selection conditions, i.e., in organ
cultures of F5/RAG-12 lobes expressing the positively se-
lecting ligand (H-2Db). Under identical culture conditions,
z15% of thymocytes in F5/RAG-12 lobes are CD81,
which corresponds to z8 3 104 TCRhi CD81 cells/lobe
(not shown).
CD3e Ligation Promotes CD81 Differentiation in Thymuses
Expressing MHC Class II–restricted and Polyclonal TCRs.
The effect of CD3fos-F(ab9)2 on CD81 cell differentiation
was not restricted to thymocytes expressing a transgenic
MHC class I–restricted TCR, as CD81 cells also differenti-
ated to maturity in thymuses expressing a MHC class II–
restricted TCR, A18 (25), on a RAG-12 background (Fig.
1  B) or polyclonal, endogenously rearranged TCRs in
b2m2 mice (Fig. 1 C). CD81 cell maturation was found to
be much less efficient in the latter, and even a 10-fold in-
crease in the concentration of CD3fos-F(ab9)2 induced only
a moderate 2–3-fold increase in mature TCR-a/bhi CD81
cells (Fig. 2), considerably fewer than could be generated
from mice with transgenic TCRs (5–10-fold increase, Fig.
2). These differences in efficiency of CD81 generation may
reflect the presence of the rearranged TCR in transgenic
mice, but they also correlate with the extent of competi-
tion for differentiation to the CD4 lineage ongoing in these
lobes. That is, although under normal culture conditions no
CD41 T cells differentiate in lobes from F5/RAG-12 mice,
class II–restricted A18/RAG-12 lobes generate z30%
CD41 cells, whereas b2m2 thymus lobes, which have en-
dogenous TCR rearrangement, generate z70% CD41 cells
over an equivalent culture period. Commitment to the CD4
lineage in these b2m2 lobes is so efficient that CD3fos-
F(ab9)2 treatment may not be able to redirect these com-
mitted cells to the CD8 lineage.
We tested whether this was the case by examining
whether we could improve the efficiency of CD81 cell
maturation by using thymus lobes from MHC2 mice in
which there is no competition for commitment to the
CD4 lineage. As shown in Fig. 1 D, CD3fos-F(ab9)2 was
able to promote more efficient maturation of thymocytes
to the CD8 lineage in MHC2 lobes than in b2m2 lobes,
such that the number of mature, TCR-a/bhi CD81 cells
generated approached that obtained with TCR transgenic
lobes (Fig. 2). However the concentration of CD3fos-
F(ab9)2,which promoted maximal CD81 differentiation in
MHC2 mice, was z5-fold higher than was required for in-
ducing differentiation of CD81 cells in mice expressing a
transgenic TCR (Fig. 2). It is likely that the requirement
for higher concentrations of the F(ab9)2 reagent reflects dif-
ferences in the level and timing of expression of the trans-
genic TCRs relative to mice expressing endogenous
TCRs. For both b2m2 and MHC2 thymocytes, we could
confirm that the CD81 cells generated were of the a/b
lineage as they showed upregulated TCR upon staining
with a pan–TCR-b antibody, H57.597.
Figure 2. CD3fos-F(ab9)2 induces a significant increase in the number
of mature CD81TCR-a/bhi T cells in neonatal thymus lobes. Lobes
were cultured as in Fig. 1, with the indicated concentrations of CD3fos-
F(ab9)2, whereupon thymocytes were stained for CD4, CD8, and TCR-b
(KT11.5, F23.1, or H57.597) and analyzed by FACSÒ. Mature, TCRhi
cells were gated and absolute numbers of CD81TCRhi cells were calcu-
lated for each lobe. Data are presented as the means 6 SE of CD81TCRhi
cells recovered from groups of 3-4 individual lobes. The extent of the in-
crease in CD81TCRhi cells in CD3fos-F(ab9)2–treated cultures compared
with medium only is indicated above each experiment. Two independent
experiments are shown for F5/RAG-12/b2m2 and A18/RAG-12 lobes
and a titration of CD3fos-F(ab9)2 for MHC2 lobes. The total numbers of
thymocytes recovered from each group were, respectively: F5/RAG-12/
b2m2: experiment 1, 53 6 7 3 104 (medium) and 51 6 6 3 104 (5 mg/ml);
experiment 2, 14 6 5 3 104 (medium) and 43 6 10 3 104 (5 mg/ml);
A18/RAG-12: experiment 1, 10 6 1 3 104 (medium) and 33 6 4 3 104
(5 mg/ml); experiment 2, 20 6 6 3 104 (medium) and 25 6 3 3 104 (5 mg/
ml); MHC2: 108 6 32 3 104 (medium), 91 6 1 3 104 (5 mg/ml), 55 6 5
3 104 (20 mg/ml) and 5765 3 104 (40 mg/ml); and b2m2 lobes: 42 6 7
3 104 (medium) and 49 6 1 3 104 (50 mg/ml). 
Figure 3. CD81 T cells re-
covered from CD3fos-F(ab9)2–
treated F5/RAG-12b2m2 thy-
muses are functionally mature
CTL precursors. CTL activity
shown is of cells recovered from
CD3fos-F(ab9)2–treated F5/
RAG-12b2m2 thymuses (circles)
or medium control thymuses (tri-
angles). Thymocytes recovered
from equivalent numbers of cul-
tured lobes/group were stimu-
lated with NP68 peptide-pulsed
DCs for 4 d and tested for cy-
tolytic activity on peptide-loaded
(filled symbols) or control (open
symbols) EL-4 target cells in a
standard 4-h 51Cr–release assay.
The effector ratio is presented as
responder dilution as cells recov-
ered from stimulation cultures were
resuspended to the same volume.1253 Basson et al.
We have shown previously that CD3/CD4 or CD3/
CD8 BsAbs can promote differentiation of CD41 cells in
TOCs (4). CD4 maturation required a minimum of 16 h of
incubation with BsAb followed by a further 24–48 h of in-
cubation in medium alone before significant numbers of
mature CD41 cells were detected. In contrast, for maximal
CD81 thymocyte differentiation we routinely cultured the
lobes for 3 d with CD3fos-F(ab9)2 followed by a further
3–4 d of culture in medium alone. Shorter incubation
times with CD3fos-F(ab9)2 were not optimal for CD81 dif-
ferentiation. Although CD81 cells could be detected in
cultures at earlier times after the lobes were changed into
medium without Ab, the cells that appeared were pheno-
typically immature, in that they expressed high levels of
HSA and reduced levels of TCR (as we previously re-
ported for MHC2 mice [4]). We observed a gradual matu-
ration of the population to TCRhi HSAlo phenotype in the
48–72 h after Ab removal. This difference in the timing re-
quired for maturation of CD41 versus CD81 cells is similar
to that which has been reported in vivo (30).
CD3fos-F(ab9)2 Blocks Maturation of CD41 Thymocytes.
It appeared that CD3fos-F(ab9)2 was less efficient at redi-
recting thymocytes to the CD8 lineage where there was
overt competition for maturation to the CD4 lineage, par-
ticularly in b2m2 lobes (Fig. 2). However, we also ob-
served that there was a significant influence of CD3fos-
F(ab9)2 treatment on the transition from DP to CD41 cells
in thymuses from A18/RAG-12 (Fig. 1 B) and b2m2 (Fig.
1 C) mice. The percentage of CD41 cells was reduced by
four- to sixfold after culture with CD3fos-F(ab9)2 com-
pared with medium, and, strikingly, the remaining CD41
cells were largely immature, in that they failed to fully
downregulate HSA (Fig. 1, B and C). This decrease in
CD4 maturation generally corresponded to up to an in-
crease of up to twofold in the number of DP thymocytes
present in treated thymuses, suggesting that CD3fos-F(ab9)2
blocked normal differentiation of immature CD4-commit-
ted thymocytes. Thus, it appears that CD3fos-F(ab9)2
 spe-
cifically inhibits the maturation of CD41 cells in TOCs,
similar to what has been reported for antagonistic MHC class
II–restricted altered peptide ligands (7).
Unlike intact 2C11 Ab (31, 32), CD3fos-F(ab9)2 does
not stimulate thymocyte transition from DN to DP subsets
in organ cultures from RAG2 mice (data not shown), nor
induce proliferation of thymocytes (shown in Fig. 4), mak-
ing it unlikely that CD3fos-F(ab9)2 actively promotes the
generation of DP thymocytes. However, it is possible that
CD3fos-F(ab9)2 to some extent promotes survival of DP
thymocytes as there was a two- to threefold increase in to-
tal numbers of thymocytes recovered from treated lobes
compared with medium controls in about half of the ex-
periments (see legend to Fig. 2).
CD81 Thymocytes Induced by CD3e Ligation Can Differen-
tiate into Effector CTLs. The CD81 cells recovered from
CD3fos-F(ab9)2–treated cultures looked phenotypically
mature as indicated by downregulated HSA (Fig. 1 A) and
high TCR levels (shown in Fig. 5). To test whether they
were functionally mature, we took lobes from F5/RAG-
12/b2m2 mice cultured with CD3fos-F(ab9)2 or medium
as described above, and asked whether the mature CD81
cells could differentiate to effector CTLs when stimulated
with B10 (H-2b) DCs, loaded with the antigenic H-2Db-
binding NP68 peptide. After 4 d of culture with stimulator
cells in the presence of IL-2, efficient lysis of NP68-loaded
H-2Db target cells, but not control targets, was detectable
(Fig. 3). Control lobes from F5/RAG-12/b2m2 mice, cul-
tured in medium alone, contained a few CD81 T cells (as
shown in Fig. 1 A), which were also capable of expanding
upon stimulation with peptide-pulsed DCs in the presence
of IL-2 and maturing into cytotoxic T cells.
CD3fos-F(ab9)2 Does Not Stimulate T Cell Proliferation but
Causes TCR Downmodulation. To investigate the signals
induced by CD3fos-F(ab9)2 in thymocytes, we examined its
ability to induce T cell proliferation. In contrast to native
parental antibody, 145.2C11, which induces strong prolif-
eration of mature thymocytes, CD3fos-F(ab9)2 did not
stimulate any detectable proliferation over a wide concen-
tration range (Fig. 4), as has been previously reported for
peripheral T cells (16, 17). CD3/CD4 and CD3/CD8 F(ab9)2s
were able to stimulate thymocyte proliferation also, al-
though not as effectively as 2C11 Ab, indicating that coli-
gating the coreceptor with CD3 can replace to some extent
the contribution provided by the Fc portion of intact anti-
body.
As CD3fos-F(ab9)2 did not stimulate proliferation, we
asked whether it caused downmodulation of the TCR–CD3
complex (33–35) when added to TOCs. Indeed, effective
downregulation of TCR–CD3 complex on thymocytes
was evident 18 h (day 1) after addition of the antibodies,
and reached a maximum within 3 d (Fig. 5). TCR down-
modulation was comparable for CD3fos-F(ab9)2 and the in-
tact 2C11 antibody, suggesting that these reagents engaged
equivalent numbers of CD3e molecules (35). Removal of
the antibodies on day 4 resulted in gradual reexpression of
Figure 4. CD3fos-F(ab9)2 can-
not induce proliferation in ma-
ture thymocytes. Shown is pro-
liferation of B10 thymocytes to
anti-CD3 mAb (2C11), CD3/
CD8 and CD3/CD4 BsAb, and
CD3fos-F(ab9)2 (CD3/CD3), as
indicated. B10 thymocytes (106/
well) were incubated for 72 h in
96-well plates with antibodies.
Cultures were pulsed with 1 mCi
[3H]thymidine/well for the last
18 h of culture, harvested, and
counted in a beta counter with
scintillation.1254 CD3e Ligation Induces CD81 Thymocyte Maturation
the TCR–CD3 complex on DP and CD81 thymocytes,
up to normal levels by day 6. Although extensive deletion
of DP thymocytes was evident in 2C11-treated lobes, as
previously described (31), none was observed after CD3fos-
F(ab9)2 treatment, but rather differentiation of mature
CD81 cells with upregulated TCR (Fig. 5). It is also of in-
terest to note that both CD3fos-F(ab9)2 and CD3/CD4
were effective at inducing TCR modulation on thymocytes
in suspension culture (data not shown), and yet CD3fos-
F(ab9)2 failed to induce any proliferation. Furthermore, this
effect was not specific for thymocytes as CD3fos-F(ab9)2
caused equivalent TCR downmodulation on peripheral T
cells (data not shown). These observations support data from
Cai et al. (35), who showed that TCR modulation in re-
sponse to TCR engagement does not necessarily correlate
with the efficacy of T cell activation.
CD3fos-F(ab9)2 Is a Potent Antagonist of Primary T Cell Re-
sponses. The biological effects of CD3fos-F(ab9)2 in TOCs
are clearly reminiscent of the effects of some altered peptide
ligands with antagonist/partial agonist activity, namely the
following: the ability to promote the maturation of CD81
thymocytes in vitro (5, 6, 9); to interfere with normal CD41
thymocyte maturation, referred to as “competitive antago-
nism” (7); to downmodulate the TCR–CD3 complex (34);
and the inability to induce proliferation of mature T cells
(36–39). Therefore, we tested whether CD3fos-F(ab9)2, was
able to antagonize an antigen-specific response at concen-
trations similar to those inducing CD8 differentiation. Fig.
6 shows that addition of CD3fos-F(ab9)2 inhibits prolifera-
tion of primary cultures of peripheral T cells from either
class II–restricted, CD41 A18 transgenic TCR-expressing
cells (Fig. 6 A) or class I–restricted, CD81 T cells from F5/
Rag-12 transgenic mice (Fig. 6 B), to a range of concentra-
tions of the agonist peptide. For F5 spleen cells at subopti-
mal peptide concentration (1 nM), as little as 1.5 mg/ml
CD3fos-F(ab9)2 gave .90% inhibition of the response (data
not shown).
It has been reported previously that nonstimulatory anti-
CD3 antibodies are able to induce functional anergy in T
cell clones (17) by delivering a set of distinct intracellular
signals (see below). Although unlikely, it was possible that
CD3fos-F(ab9)2 was sterically interfering with TCR recog-
nition of MHC/peptides. This did not appear to be the
case for F5 TCR transgenic mice, as CD3fos-F(ab9)2 did
not interfere with differentiation of CD81 cells in organ
culture (4). However, to exclude the possibility that steric
Figure 5. 2C11-derived CD3fos-F(ab9)2 (CD3/CD3) and intact 2C11 induce equivalent downmodulation of the TCR–CD3 complex on thymocytes
in F5/RAG-12b2m2 neonatal lobes. Neonatal lobes were cultured as in Fig. 1 in the presence of 10 mg/ml 2C11 or CD3fos-F(ab9)2 (CD3/CD3) for 4 d,
transferred to fresh medium on day 4, and cultured for a further 2 d. Individual lobes were harvested on days 1, 3, and 6 of culture and analyzed by flow
cytometry. TCR expression for DP (thick line) and CD81 (filled histograms) populations are shown for each time and treatment. CD4 and CD8 staining of
thymocytes recovered on day 6 of culture is shown with the percentages of DP and CD81 cells indicated.1255 Basson et al.
hinderance was preventing TCR transgenic cells from in-
teracting with MHC, we examined upregulation of CD69
in response to peptide when CD3fos-F(ab9)2 was present in
the culture. As shown in Fig. 6 C, both CD41 A18 T cells
and CD81 F5 T cells upregulated CD69 to a comparable
extent in wells containing peptide or peptide plus CD3fos-
F(ab9)2. Proliferation in parallel cultures was inhibited by
z50% (A18) and 98% (F5) in the presence of CD3fos-
F(ab9)2 for this particular experiment (data not shown).
Therefore, CD3fos-F(ab9)2 does not appear to inhibit early
TCR recognition events but may subsequently alter intra-
cellular signals induced during antigen recognition by ma-
ture T cells (17).
Tyrosine Phosphorylation Signals Involved in CD81 Lineage
Commitment. Early tyrosine phosphorylation events in
mature T cells in response to CD3/CD4 and CD3fos-
F(ab9)2 have been studied in detail (16, 17). Using identical
reagents to those used in this study, it was shown that in T
cell clones, CD3/CD4 BsAb induced tyrosine phosphory-
lation patterns characteristic of an agonist signal, whereas
CD3fos-F(ab9)2 induced signals indistinguishable from those
generated by partial agonist/antagonist ligands (16, 17).
We compared signals initiated by CD3/CD4 BsAb,
which behaves as an agonist and induces CD4 maturation,
with those transduced by the antagonist, CD3fos-F(ab9)2,
in immature thymocytes from F5/RAG-12/b2m2 mice.
As there are no mature CD41 or CD81 cells in ex vivo
thymocytes from these mice, we were able to look at the
effects of these reagents on unmanipulated immature cells,
i.e., those which had not been subject to antibody-medi-
ated selection. Perhaps not surprisingly, we observed some
differences to what has been reported for T cell clones (16).
Both CD3/CD4 and CD3fos-F(ab9)2 induced hyperphos-
phorylation of the constitutively phosphorylated TCR-z
chain, p21 (40, 41), resulting in the appearance of the p23
isoform (Fig. 7 A). However, unlike CD3/CD4 BsAb,
CD3fos-F(ab9)2 did not stimulate phosphorylation of p27,
identified as CD3e (16). This observation is of particular
relevance given recently reported differences in the down-
stream effector molecules, which are able to interact with
phosphorylated TCR-z versus CD3e immunoreceptor ty-
rosine-based activation motif (42), which may have distinct
consequences for engaging downstream signaling pathways
(43).
In all cases, similar amounts of ZAP-70 protein were
found associated with phospho-z proteins in stimulated and
unstimulated thymocytes (Fig. 7 B). However, phosphory-
lated ZAP-70 was present only in cells stimulated with
CD3fos-F(ab9)2 and CD3/CD4 BsAb and not in control
CD4jun-F(ab9)2–stimulated or unstimulated cells (Fig. 7 C).
At 5 min of stimulation, tyrosine-phosphorylated ZAP-70
was apparent in the CD3fos-F(ab9)2–treated thymocytes,
but at slightly lower levels than in the CD3/CD4 BsAb-
treated group, and by 20 min levels of phospho–ZAP-70
had further diminished in the former, whereas they were
maintained at relatively high levels in the latter (Fig. 7 C).
These observations differ from studies in T cell clones, in
which differences were noted in TCR-z phosphorylation
and no ZAP-70 phosphorylation was detected after stimu-
lation with altered peptide ligands (16, 38, 44, 45) or
CD3fos-F(ab9)2 (16, 17), and may reflect the fact that
TCR-z chains are constitutively phosphorylated in ex vivo
Figure 6. CD3fos-F(ab9)2 antagonizes the proliferative response of mature CD41 and CD81 T cells to antigen. (A) Antagonist activity of CD3fos-
F(ab9)2 is shown by its inhibitory effect at 1.25 mg/ml CD3fos-F(ab9)2 on the proliferation of spleen cells from A18/RAG2 mice to various concentra-
tions of C5 peptide and (B) at 12.5 mg/ml on the proliferation of F5/RAG-12 spleen cells to NP68 peptide. The same concentrations of a nonbinding
F(ab9)2, CD4/CD4 (B only), and a binding, nonantagonistic antibody, anti–Thy-1 (YTS 154.7), are included as controls. (C) CD69 is upregulated on
A18 and F5 spleen cells cultured with 200 nM C5 peptide for 22 h (A18) or 10 nM NP68 for 1.5 h (F5) (light fill), and to an equivalent extent in the pres-
ence of 62.5 ng/ml (for A18) or 625 ng/ml (for F5) CD3fos-F(ab9)2 plus peptide (solid line). No CD69 expression is observed in the absence of antigen
(data not shown) or in cultures with CD3fos-F(ab9)2 alone (dark fill).1256 CD3e Ligation Induces CD81 Thymocyte Maturation
thymocytes (40, 41). Given the essential role of ZAP-70 in
the maturation of both CD4 and CD8 lineages in the
mouse thymus (46), it is perhaps not surprising that both
CD4 and CD8 differentiation signals should induce some
level of ZAP-70 activation.
To examine whether differences observed in thymocytes
after stimulation with CD3/CD4 or CD3fos-F(ab9)2, could
be attributed to a lack of coreceptor-associated p56lck re-
cruitment to the signaling complex by CD3fos-F(ab9)2, we
examined p56lck immunoprecipitates from F5/RAG-12/
b2m2 thymocyte lysates for the presence of coprecipitating
tyrosine phosphoproteins. Fig. 7 D clearly demonstrates the
physical juxtaposition of p56lck with high levels of p21 as
well as p23 phospho-z and p27 CD3e in thymocytes after
ligation with CD3/CD4, and to a lesser extent (p21 and
p23 phospho-z) with CD3/CD8 BsAbs, in agreement with
reported differences in the levels of p56lck associated with
CD4 and CD8 (19). In contrast, only low levels of p21
phospho-z were detected in p56lck precipitates from CD3fos-
F(ab9)2-stimulated lysates (Fig. 7 D). After treatment with
all stimuli, a 70-kD phosphoprotein that was confirmed to
be ZAP-70 by Western blotting with specific antisera (data
not shown) was also found to be associated with p56lck pre-
cipitates. Note that low levels of phospho–ZAP-70 copre-
cipitated with p56lck in unmanipulated thymocytes kept on
ice. ZAP-70 was rapidly dephosphorylated upon incuba-
tion at 378C so that virtually no phospho–ZAP-70 could
be detected in unstimulated thymocytes at 378C. The low
level of phospho–ZAP-70 was maintained in CD3fos-
F(ab9)2–stimulated thymocytes and increased in CD3/CD4
and CD3/CD8–stimulated cells. Thus, although not com-
pletely devoid of p56lck upon CD3fos-F(ab9)2 stimulation,
the extent to which phosphorylated CD3/TCR chains are
associated with p56lck appears to be significantly less than
after CD3/CD4 stimulation, and may be insufficient for
sustaining high levels of phospho–ZAP-70 (47). As we
have previously shown that CD3/CD4, and to a lesser ex-
tent CD3/CD8, BsAb promote differentiation of CD41
thymocytes (4), and show here that CD3fos-F(ab9)2 effi-
ciently promotes differentiation of CD81 thymocytes, these
data indicate that these differences in signaling underlie the
differential commitment between the two lineages.
Discussion
The signals required for CD4 differentiation seem to be
relatively promiscuous in that coengagement of the TCR
with a large number of surface molecules can induce CD41
differentiation in immature thymocytes even in the absence
of MHC class II molecules (1, 3, 4). CD8 differentiation,
on the other hand, seems to require specific signals and
MHC class I expression (48). In this study we show that
TCR engagement in the absence of coaggregation of other
surface receptors (in particular those associated with p56lck)
can exclusively induce differentiation of the CD8 lineage.
We show that the signal that induces CD8 differentia-
tion, i.e., ligation with CD3fos-F(ab9)2, is unable to stimu-
late proliferation in mature T cells and can act as a func-
tional antagonist for antigen-specific peripheral T cell
responses. Moreover, this reagent induces a set of intracel-
lular tyrosine phosphorylation patterns in thymocytes,
namely, hyperphosphorylation of CD3z, no phosphoryla-
tion of CD3e, and altered levels and kinetics of ZAP-70
phosphorylation, distinct from that induced by CD3/CD4
BsAb, which promotes CD4 differentiation. Furthermore,
we can correlate these distinct signaling patterns to the as-
sociation of lck with the TCR complex because, not sur-
prisingly, CD3/CD4 coligation with BsAbs induces very
stable TCR–lck association, whereas CD3 ligation alone
does not. In mature T cells, recruitment of p56lck to the
TCR complex seems to be an essential feature of TCR sig-
naling leading to T cell activation, whereas TCR engage-
ment in the absence of sufficient p56lck activation leads to
partial, antagonist-like signals (16). Such partial signals can
be generated in mature T cells either by altered peptide
ligands or by CD3fos-F(ab9)2 reagents, identical to those used
here (16, 17). Given the sparse knowledge on the integra-
tion of the various signaling pathways involved in thy-
Figure 7. Distinct patterns of
tyrosine phosphorylation are in-
duced in immature F5/RAG-
12b2m2 thymocytes by stimula-
tion with CD3/CD4 BsAb and
CD3fos-F(ab9)2. (A) Thymocytes
were stimulated with F(ab9)2 reagents, as indicated, for 8 min at 378C.
Lysates were immunoprecipitated with anti–TCR-z mAb and the pre-
cipitates immunoblotted with antiphosphotyrosine mAb (4G10), to re-
veal differences in TCR-associated phosphotyrosine-containing proteins.
(B) Total ZAP-70 proteins associated with TCR-z polypeptides were
examined in unstimulated or F(ab9)2-stimulated samples (5 min at 378C),
as indicated. Lysates were immunoprecipitated with anti–TCR-z and immu-
noblotted with anti–ZAP-70 mAb. (C) Tyrosine phosphorylation of ZAP-70
proteins in control or F(ab9)2-stimulated thymocytes was visualized by
immunoprecipitating cell lysates with polyclonal anti–ZAP-70 serum af-
ter stimulation of thymocytes for 5 and 20 min at 378C, as indicated, and
immunoblotting was with antiphosphotyrosine 4G10. Half of the 20-min
precipitate was probed with anti–ZAP-70 mAb to confirm that equiva-
lent amounts of protein were present. (D) p56lck immunoprecipitates
demonstrate different association with TCR-associated phosphoproteins.
Thymocytes were stimulated with F(ab9)2-reagents at 378C for 5 min, as
indicated, or left on ice throughout (48C). Cell lysates were precipitated
with p56lck-antiserum and immunoblotted with antiphosphotyrosine (4G10).1257 Basson et al.
mocyte differentiation, at this stage we are unable to fur-
ther correlate differences in p56lck recruitment to the
activation of unique downstream signaling pathways.
However, it is clear that these differences induce distinct
biological effects both in immature thymocytes and mature
T cells.
There have been a number of different models proposed
over the years to explain how lineage choices are made in
the thymus. Most recent models have explained these
choices in terms of quantitative differences in signaling (18,
49). In essence they propose a linear gradation of signaling,
starting with signals so low that thymocytes die of neglect,
progressing through weak signals suitable for CD8 differen-
tiation, to stronger signals that are suitable for CD4 differ-
entiation, and finally, to yet stronger signals that induce ap-
optosis. Although a number of experimental observations
fit well with such models, others do not. For example, in
support of the quantitative models, it has been shown that
constitutive expression of CD8 transgenes (50), and more
particularly, hybrid CD8 transgenes with CD4 cytoplasmic
domains (18), cause cells expressing class I–restricted trans-
genic TCRs to be selected into the CD4 lineage. These
coreceptor transgenes would be predicted to increase the
sensitivity of thymocytes to signals, with the observed con-
sequence that they change their commitment from the
CD8 to CD4 lineage. In contrast, other studies have shown
that some altered peptide ligands, which induce efficient
maturation of CD81 TCR transgenic cells, do not alter the
commitment of these cells to the CD4 lineage at higher
peptide concentration, but instead induce deletion (5, 10,
51). A quantitative signaling model would predict that in-
creasing the peptide concentration should provide a linear
increase in signal strength which at some point should be
suitable for CD4 commitment. The observation that the
transgenic thymocytes are instead deleted, is difficult to
reconcile with these current models.
We suggest a novel model of thymocyte differentiation
(illustrated in Fig. 8) incorporating the idea that antagonist/
partial agonist–like signals per se may be responsible for
commitment to the CD8 lineage, as shown for some antag-
onist and partial agonist peptides (5, 39) and in the present
study. The main difference from previous schemes is that
we propose that T cells integrate two distinct signals, one
provided by ligation of the TCR, and the second provided
by the activation of lck. We suggest that it is the relative ra-
tio of these two signals that leads to distinct differentiation
decisions in the thymus. Thus, within a simple continuum,
insufficient signals would lead to death by neglect, whereas
CD8 differentiation would be signaled by TCR engage-
ment combined with very little lck activation; if the com-
bined TCR/lck signal is too strong, deletion results; but
changing the ratio, to increase the lck signal relative to the
TCR signal, promotes CD4 differentiation.
Therefore, as indicated in Fig. 8, CD8 differentiation is
signaled by engagement of the TCR in the absence of
overt lck signals, which is equivalent to the signals deliv-
ered in mature T cells by recognition of antagonist/partial
agonist peptides. Although expression of CD8a/b het-
erodimers are obligatory for normal differentiation of this
lineage (52–55), two recent papers (51, 56) together with
our own data indicate that the participation of CD8 is not
mandatory. We presume the primary role of CD8 in the
thymus is to stabilize TCR–MHC interactions without
contributing strong lck signals. This would fit both with
the reported weak association of CD8a polypeptides with
lck (19), and the observation that CD8a9/b heterodimers,
which cannot associate with lck, are tolerated in mouse
thymus (57). Interestingly, in CD42 thymocytes a number
of class II–restricted transgenic TCRs have been shown to
be selected efficiently into the CD8 lineage (49). Accord-
ing to our model, the absence of CD4 in these thymocytes
would selectively reduce the lck signal, altering the balance
in favor of a predominant TCR signal, thus changing the
commitment of these cells to the CD8 lineage.
CD4 associates very efficiently with lck and engagement
of TCR plus CD4 would favor an lck-biased signal, thus
promoting CD4 lineage commitment. Given the promi-
nent involvement of lck, we would predict that signals suit-
able for CD4 differentiation would tend to resemble weak
agonist signals, capable of inducing full activation of mature
T cells. Indeed CD41 T cells selected on single MHC/
peptide ligands in the thymus have been shown to be able
to proliferate in response to the selecting peptide (58). As
lck is relatively promiscuous in its associations, engagement
of a variety of molecules, e.g., CD4, CD8, or CD2, with
the TCR could provide sufficient lck activity to favor CD4
differentiation (1, 3, 4). Furthermore, ligation of CD4 with
anti-CD4 Abs, which has been shown to promote lck ac-
tivity (59), enhances maturation of CD41 thymocytes in-
duced by anti-TCR or bispecific antibodies (4, 60). These
Figure 8. A model of thymocyte differentiation in which the relative
balance of signals delivered by TCR engagement and lck activation is re-
sponsible for directing commitment to the CD4 and CD8 lineages. En-
gagement of TCR with particular MHC/peptide ligands can give partial
antagonist–like signals with relatively little lck activation that is appropri-
ate for commitment to the CD8 lineage in the thymus. Increasing the
concentration of such peptides may increase the TCR engagement and
promote an lck signal, which results in deletion but not differentiation to
the CD4 lineage. In contrast, MHC/peptide interactions that result in a
relatively high lck to TCR signal ratio specify commitment to the CD4
lineage. Thus overexpression of coreceptors with class I TCR transgenes
could disproportionately increase the lck signal relative to the TCR signal
and result in commitment to the CD4 lineage. On the other hand, class
II–restricted TCR transgenes on a CD48 background would not receive a
CD4-associated lck signal upon MHC/peptide engagement, leading to a
predominant TCR to lck signal, which would favor commitment to the
CD8 lineage.1258 CD3e Ligation Induces CD81 Thymocyte Maturation
results indicate that lck activation in the presence of weak
TCR signals do indeed favor CD4 commitment.
Our model requires that different TCR-MHC/peptide
ligand combinations can give different ratios of TCR ver-
sus lck signals, which is known to occur in mature T cells.
The interaction of T cells with partial agonist/antagonist
ligands has been shown to result in a distinct set of bio-
chemical signals (61), which appear to differ from full acti-
vation signals due to insufficient recruitment of active lck
to the TCR (49). Moreover, other TCR-MHC/peptide
ligand interactions induce lck activity independently of the
coreceptors. In these CD4- and CD8-independent periph-
eral T cell responses, full activation can be achieved when
no coreceptors are present (62, 63). As lck has been shown
to be required for T cell activation (64), it is generally sup-
posed that these coreceptor-independent responses occur
because particular TCR-MHC/peptide interactions are
able either to recruit sufficient active lck to the TCR sig-
naling complex, or that another src-family kinase, e.g., fyn,
can cooperate to promote full activation. This is in contrast
to many TCR-MHC/peptide combinations, which re-
quire coreceptors and TCRs to cooperatively bind MHC
molecules in order to exceed the stimulation threshold. It is
currently unknown whether interactions between specific
TCR-MHC/peptide combinations produce these differen-
tial outcomes as a result of differences in ligand density,
TCR affinity, the ability to induce specific conformational
changes in the TCR upon ligand binding, inherent vari-
ability in the interaction between particular TCRs and in-
tracellular signaling molecules, or combinations of these.
For the purposes of the model, it is sufficient to be aware
that examples exist in mature T cells of individual TCR-
MHC/peptide engagements that can induce TCR signals
with a range of lck activity from very little to high levels,
and we propose the same holds true for thymocytes. We
would account for the presence of MHC class II–restricted
“CD4-manqué” cells in CD42 mice as examples of thy-
mocytes expressing TCRs that behave in a coreceptor-
independent fashion. That is, just as with some mature T
cells, the engagement of their TCRs in the absence of
coreceptor activates sufficient src-family kinases to direct
maturation to the CD4 lineage.
Unlike quantitative signaling models, and as illustrated in
Fig. 8, we can explain the failure of high concentrations of
partial agonist peptides to drive class I–restricted transgenic
TCRs into the CD4 lineage, as an inherent failure of these
peptides to shift the TCR/lck signal balance to that re-
quired for CD4 commitment. Increasing the concentration
of peptide simply increases the overall signal in these cells,
shifting the curve to the right in Fig. 8, which drives the
thymocytes to deletion. Similarly, some partial agonist pep-
tides (56) may never be appropriate to induce CD8 differ-
entiation, because when they engage the TCR too much
lck is activated. An example may be the lymphocytic chorio-
meningitis virus variant peptide, A3V, which appears to be
recognized by mature T cells in a CD8-independent man-
ner (56) supporting the view that it induces relatively high
lck activity, which would be inappropriate for CD81 dif-
ferentiation in our model.
A prediction of the scheme outlined in Fig. 8 is that an-
tagonist peptides would not be appropriate for selection of
CD41 cells. Thus far, an MHC class II-binding antagonist
peptide has been shown to inhibit, rather than promote,
the maturation of specific TCR transgenic CD41 T cells
(7), similar to the results reported here after treatment of
lobes with CD3fos-F(ab9)2. Furthermore, selection by a
single peptide/MHC class II complex, where the peptide
had been shown to possess antagonist properties, generated
a repertoire of CD41 cells that could not be antagonized by
the same peptide in the periphery (65). It will be interesting
to see whether this prediction will generally hold true.
In conclusion, our results suggest that engaging CD8a/b
or CD4 coreceptors during thymocyte differentiation has
distinct outcomes, resulting in differential recruitment of
signaling mediators that direct commitment decisions. As
the CD3fos-F(ab9)2 reagent mimics uniquely the receptor
engagements appropriate for differentiation of CD81 thy-
mocytes, we are now in a position to be able to examine
some of the downstream signaling cascades controlling lin-
eage commitment.
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